Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Placenta-specific 8 (PLAC8)
- Target
- PLAC8
- Molecular classification
- Other
01
Overview
PLAC8 (placenta-specific 8, ONZIN, C15) is an intracellular cysteine-rich protein implicated in chromatin binding, regulation of transcription, control of autophagy, cell proliferation, apoptosis, and immune modulation. It is widely expressed in epithelial, immune, and placental tissues, and functions in disease states such as cancer (promoting EMT and chemoresistance), viral infections (modulating the host immune response and directly facilitating viral replication), metabolic disorders, and inflammation. Elevated PLAC8 correlates with disease progression, poor prognosis, and resistance to therapy in several malignancies and may act as a critical biomarker and therapeutic target in relevant pathologies.
- Other names
- ONZINC15Placenta Associated 8
02
Mechanism of action
Drugs (chemotherapy) resistance via autophagic flux inhibition; Modulation of EMT (epithelial-mesenchymal transition); Suppression/activation of immune pathways (e.g., TLR7/MyD88/NF-κB signaling).
03
Biological functions
Chromatin bindingRegulation of transcription by RNA polymerase IIAutophagy regulationCell cycle regulationImmune response modulationCell proliferationApoptosis regulationThermogenesis regulation
04
Disease associations
Cancer (colon, breast, lung, prostate, pancreatic, cervical, renal, hepatic, osteosarcoma, neuroendocrine tumors)ChemoresistanceViral infection (SARS-CoV-2, duck hepatitis A virus, Enterovirus 71)Inflammation (Adult Still Disease, interstitial cystitis)Stemness and radiotherapy resistance
05
Safety considerations
Because PLAC8 promotes cancer progression, invasion, metastasis, and chemoresistance, targeting it may entail risks of unintended immune suppression, altered autophagy, and on-target toxicity in healthy tissues
06
Interacting drugs
No direct pharmacological agents targeting PLAC8 are validated or approved; interacts with chemotherapy agents indirectly by modulating chemoresistance, such as adriamycin in breast cancer
07
Biomarkers
PLAC8 expression is a biomarker candidate for multiple cancers (tumor aggressiveness, chemoresistance, prognosis)immunotherapy responsiveness in renal cell carcinomapotential viral infection severity
Beyond the preview
Go deeper on Placenta-specific 8 (PLAC8).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Placenta-specific 8 (PLAC8).